The Allergan-Valeant fight is already changing how doctors think about their prescription habits.
The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.
Bernstein analyst Ronnie Gal created the survey and notes that the answers are all well and good, but doctors have few alternatives.
